OrsoBio

OrsoBio Announces Oversubscribed $67 Million Series B Financing to Accelerate Mitochondrial Protonophore Portfolio Targeting Obesity and Associated Disorders
Businesswire
Fri, 09/6/24 - 10:50 am
OrsoBio
obesity
funding
An obesity drug biotech gets buy-in from Eli Lilly, venture firms
BioPharma Dive
Tue, 11/7/23 - 09:50 am
OrsoBio
Eli Lilly
funding
obesity
diabetes